Correlation of platelet activating factor and age-related macular degeneration

Bibliography

• Prokofyeva E, Zrenner E. Epidemiology of major eye diseases leading to blindness in Europe: a literature review. Ophthalmic Res 2012;47(4):171-88
   PubMed Web of Science ®Google Scholar
• Mitchell P, Wang JJ, Foran S, et al. Five-year incidence of age-related maculopathy lesions: the Blue Mountains Eye Study. Ophthalmology 2002;109(6):1092-7
   PubMed Web of Science ®Google Scholar
• Jonasson F, Arnarsson A, Eiríksdottir G, et al. Prevalence of age-related macular degeneration in old persons: age, gene/environment susceptibility reykjavik study. Ophthalmology 2011;118(5):825-30
   PubMed Web of Science ®Google Scholar
• Bressler NM, Bressler SB, Congdon NG, et al. Age-Related Eye Disease Study Research Group. Potential public health impact of Age-Related Eye Disease Study results: AREDS report no. 11. Arch Ophthalmol 2003;121(11):1621-4
   PubMed Web of Science ®Google Scholar
• Mukesh BN, Dimitrov PN, Leikin S, et al. Five-year incidence of age-related maculopathy: the Visual Impairment Project. Ophthalmology 2004;111(6):1176-82
   PubMed Web of Science ®Google Scholar
• Lim JI. Age-related macular degeneration. Informa Healthcare; New York: 2008
   Google Scholar
• Nowak JZ. Oxidative stress, polyunsaturated fatty acids-derived oxidation products and bisretinoids as potential inducers of CNS diseases: focus on age-related macula degeneration. Pharmacol Rep 2013;65(2):288-304
   PubMed Web of Science ®Google Scholar
• Whitcup SM, Sodhi A, Atkinson JP, et al. The role of the immune response in age-related macular degeneration. Int J Inflam 2013;2013:348092
   PubMedGoogle Scholar
• Ianopol N. Free radicals and eye inflammations. Oftalmologia 1998;42(1):5-9
   Google Scholar
• Mueller EE, Schaier E, Brunner SM, et al. Mitochondrial haplogroups and control region polymorphisms in age-related macular degeneration: a case-control study. PLoS One 2012;7(2):e30874
   Google Scholar
• Klaver CC, Wolfs RC, Assink JJ, et al. Genetic risk of age-related maculopathy. Population-based familial aggregation study. Arch Ophthalmol 1998;116(12):1646-51
   Google Scholar
• Kutty RK, Nagineni CN, Samuel W, et al. Differential regulation of microRNA-146a and microRNA-146b-5p in human retinal pigment epithelial cells by interleukin-1beta, tumor necrosis factor-alpha, and interferon-gamma. Mol Vis 2013;19:737-50
   PubMed Web of Science ®Google Scholar
• Klein R, Cruickshanks KJ, Nash SD, et al. The prevalence of age-related macular degeneration and associated risk factors. Arch Ophthalmol 2010;128(6):750-8
   PubMedGoogle Scholar
• Xu W, Grunwald JE, Metelitsina TI, et al. Association of risk factors for choroidal neovascularization in age-related macular degeneration with decreased foveolar choroidal circulation. Am J Ophthalmol 2010;150(1):40-47.e2
   PubMed Web of Science ®Google Scholar
• Clemons TE, Milton RC, Klein R, et al. Age-Related Eye Disease Study Research Group. Risk factors for the incidence of Advanced Age Related Macular Degeneration in the Age-Related Eye Disease Study (AREDS) AREDS report no. 19. Ophthalmology 2005;112(4):533-9
   PubMed Web of Science ®Google Scholar
• Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol 2001;119(10):1417-36
   PubMed Web of Science ®Google Scholar
• García-Layana A, Recalde S, Alamán AS, et al. Effects of lutein and docosahexaenoic Acid supplementation on macular pigment optical density in a randomized controlled trial. Nutrients 2013;5(2):543-51
   Google Scholar
• Al-Latayfeh M, Silva PS, Sun JK, et al. Antiangiogenic therapy for ischemic retinopathies. Cold Spring Harb Perspect Med 2012;2(6):a006411
   Google Scholar
• Moutray T, Chakravarthy U. Age-related macular degeneration: current treatment and future options. Ther Adv Chronic Dis 2011;2(5):325-31
   PubMedGoogle Scholar
• Rosenfeld PJ, Brown DM, Heier JS, et al. MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355(14):1419-31
   PubMed Web of Science ®Google Scholar
• Fung AT, Kumar N, Vance SK, et al. Pilot study to evaluate the role of high-dose ranibizumab 2.0 mg in the management of neovascular age-related macular degeneration in patients with persistent/recurrent macular fluid < 30 days following treatment with intravitreal anti-VEGF therapy (the LAST Study). Eye (Lond) 2012;26(9):1181-7
   PubMed Web of Science ®Google Scholar
• Brown DM, Chen E, Mariani A, et al. SAVE Study Group. Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point. Ophthalmology 2013;120(2):349-54
   PubMed Web of Science ®Google Scholar
• Martin DF, Maguire MG, Ying GS, et al. CATT Research Group. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011;64(20):1897-908
   Google Scholar
• Chakravarthy U, Harding SP, Rogers CA, et al. IVAN study investigators. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet 2013;382(9900):1258-67
   PubMed Web of Science ®Google Scholar
• Kodjikian L, Souied EH, Mimoun G, et al. GEFAL Study Group. Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: results from the GEFAL Noninferiority Randomized Trial. Ophthalmology 2013;120(11):2300-9
   PubMed Web of Science ®Google Scholar
• Friberg TR, Tolentino M, et al. LEVEL Study Group. Pegaptanib sodium as maintenance therapy in neovascular age-related macular degeneration: the LEVEL study. Br J Ophthalmol 2010;94(12):1611-17
   PubMed Web of Science ®Google Scholar
• Heier JS, Brown DM, Chong V, et al. VIEW 1 and VIEW 2 Study Groups. Intravitreal aflibercept (VEGF trap-eye) in wet age related macular degeneration. Ophthalmology 2012;119(12):2537-48
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Campochiaro PA, Shah SM, et al. Clear-It 1 Investigators. Evaluation of very high- and very low-dose intravitreal aflibercept in patients with neovascular age related macular degeneration. J Ocul Pharmacol Ther 2012;28(6):581-8
   PubMed Web of Science ®Google Scholar
• Heier JS, Boyer D, Nguyen QD, et al. CLEAR-IT 2 Investigators. The 1-year results of CLEAR-IT 2, a phase 2 study of vascular endothelial growth factor trap-eye dosed as-needed after 12-week fixed dosing. Ophthalmology 2011;118(6):1098-106
   Google Scholar
• Miller JW, Schmidt-Erfurth U, Sickenberg M, et al. Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of a single treatment in a phase 1 and 2 study. Arch Ophthalmol 1999;117(9):1161-73
   PubMedGoogle Scholar
• Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials-TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Arch Ophthalmol 1999;117(10):1329-45
   PubMed Web of Science ®Google Scholar
• Subfoveal neovascular lesions in age-related macular degeneration. Guidelines for evaluation and treatment in the macular photocoagulation study. Macular Photocoagulation Study Group. Arch Ophthalmol 1991;109(9):1242-57
   PubMedGoogle Scholar
• Schmidt-Erfurth U, Miller JW, Sickenberg M, et al. Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of retreatments in a phase 1 and 2 study. Arch Ophthalmol 1999;117(9):1177-87
   PubMedGoogle Scholar
• Woodburn KW, Engelman CJ, Blumenkranz MS. Photodynamic therapy for choroidal neovascularization: a review. Retina 2002;22(4):391-405
   Google Scholar
• Kanski Jack J. Acquired macular disorders and related conditions. Edwards R, Benson K, editors. Clinical ophthalmology, a systematic approach. 6th edition. Elsevier; USA: 2007
   Google Scholar
• Hawkins BS, Bressler NM, Miskala PH, et al. Submacular Surgery Trials (SST) Research Group. Surgery for subfoveal choroidal neovascularization in age-related macular degeneration: ophthalmic findings: SST report no. 11. Ophthalmology 2004;111(11):1967-80
   Google Scholar
• Bressler NM, Bressler SB, Hawkins BS, et al. Submacular Surgery Trials Pilot Study Investigators. Submacular surgery trials randomized pilot trial of laser photocoagulation versus surgery for recurrent choroidal neovascularization secondary to age-related macular degeneration: I. Ophthalmic outcomes submacular surgery trials pilot study report number 1. Am J Ophthalmol 2000;130(4):387-407
   PubMed Web of Science ®Google Scholar
• Abdel-Meguid A, Lappas A, Hartmann K, et al. One year follow up of macular translocation with 360 degree retinotomy in\⊂patients with age related macular degeneration. Br J Ophthalmol 2003;87(5):615-21
   Google Scholar
• Baer CA, Rickman CB, Srivastava S, et al. Recurrent choroidal neovascularization after macular translocation surgery with 360-degree peripheral retinectomy. Retina 2008;28(9):1221-7
   Google Scholar
• Barber AC, Hippert C, Duran Y, et al. Repair of the degenerate retina by photoreceptor transplantation. Proc Natl Acad Sci USA 2013;110(1):354-9
   PubMed Web of Science ®Google Scholar
• Blenkinsop TA, Corneo B, Temple S, et al. Ophthalmologic stem cell transplantation therapies. Regen Med 2012;7(6 Suppl):32-9
   Google Scholar
• Wang Y, Wang VM, Chan CC. The role of anti-inflammatory agents in age-related macular degeneration (AMD) treatment. Eye (Lond) 2011;25(2):127-39
   PubMed Web of Science ®Google Scholar
• Catchpole I, Germaschewski V, Hoh Kam J, et al. Systemic administration of Abeta mAb reduces retinal deposition of Abeta and activated complement C3 in age-related macular degeneration mouse model. PLoS One 2013;8(6):e65518
   Google Scholar
• Manjila SB, Baby JN, Bijin EN, et al. Novel gene delivery systems. Int J Pharm Investig 2013;3(1):1-7
   Google Scholar
• Thomson H, Lotery A. The promise of nanomedicine for ocular disease. Nanomedicine (Lond) 2009;4(6):599-604
   Google Scholar
• Orosz KE, Gupta S, Hassink M, et al. Delivery of antiangiogenic and antioxidant drugs of ophthalmic interest through a nanoporous inorganic filter. Mol Vis 2004;10:555-65
   PubMed Web of Science ®Google Scholar
• Jayaraman MS, Bharali DJ, Sudha T, et al. Nano chitosan peptide as a potential therapeutic carrier for retinal delivery to treat age-related macular degeneration. Mol Vis 2012;8.2300-8
   Google Scholar
• Kalishwaralal K, Barathmanikanth S, Pandian SR, et al. Silver nano - a trove for retinal therapies. J Control Release 2010;145(2):76-90
   PubMedGoogle Scholar
• Jo DH, Lee TG, Kim JH. Nanotechnology and nanotoxicology in retinopathy. Int J Mol Sci 2011;12(11):8288-301
   Google Scholar
• Singh SR, Grossniklaus HE, Kang SJ, et al. Intravenous transferrin, RGD peptide and dual-targeted nanoparticles enhance anti VEGF intraceptor gene delivery to laser-induced CNV. Gene Ther 2009;16(5):645-59
   PubMed Web of Science ®Google Scholar
• Chen H, Fan X, Xia J, et al. Electrospun chitosan-graft-poly (ϵ-caprolactone)/poly (ϵ-caprolactone) nanofibrous scaffolds for retinal tissue engineering. Int J Nanomedicine 2011;6:453-61
   PubMed Web of Science ®Google Scholar
• Chao W, Olson MS. Platelet-activating factor: receptors and signal transduction. Biochem J 1993;292:617-29
   PubMed Web of Science ®Google Scholar
• Arai H. Platelet-activating factor acetylhydrolase. Prostaglandins Other Lipid Mediat 2002;68-69:83-94
   Google Scholar
• McManus LM, Pinckard RN. PAF, a putative mediator of oral inflammation. Crit Rev Oral Biol Med 2000;11:240-58
   PubMedGoogle Scholar
• Derewenda ZS, Derewenda U. The structure and function of platelet-activating factor acetylhydrolases. Cell Mol Life Sci 1998;54:446-55
   Google Scholar
• Bhatia M. Inflammatory response on the pancreatic acinar cell injury. Scand J Surg 2005;94(2):97-102
   Google Scholar
• Sharif NA, Xu S, Hellberg PE, et al. Human conjunctival epithelial cell responses to platelet-activating factor (PAF): signal transduction and release of proinflammatory cytokines. Mol Vis 2009;15:1153-61
   PubMed Web of Science ®Google Scholar
• Okumura N, Fukushima A, Igarashi A, et al. Pharmacokinetic analysis of platelet-activating factor in the tears of guinea pigs with allergic conjunctivitis. J Ocul Pharmacol Ther 2006;22:347-52
   PubMed Web of Science ®Google Scholar
• Ma X, Ottino P, Bazan HE, et al. Platelet-activating factor (PAF) induces corneal neovascularization and upregulates VEGF expression in endothelial cells. Invest Ophthalmol Vis Sci 2004;45:2915-21
   PubMed Web of Science ®Google Scholar
• Sohn JH, Bora PS, Jha P, et al. Complement, innate immunity and ocular disease. Chem Immunol Allergy 2007;92:105-14
   PubMedGoogle Scholar
• Zinchuk O, Fukushima A, Zinchuk V, et al. Direct action of platelet activating factor (PAF) induces eosinophil accumulation and enhances expression of PAF receptors in conjunctivitis. Mol Vis 2005;11:114-23
   Google Scholar
• Hu WM, Man RY. Differential actions of platelet-activating factor (PAF) receptor antagonists on the vasodilator and vasoconstrictor effects of PAF in the rat perfused heart. Br J Pharmacol 1991;104(4):773-5
   Google Scholar
• Garland RC, Sun D, Zandi S, et al. Noninvasive molecular imaging reveals role of PAF in leukocyte-endothelial interaction in LPS-induced ocular vascular injury. FASEB J 2011;25:1284-94
   Google Scholar
• Bazan NG. Lipid signaling in neural plasticity, brain repair, and neuroprotection. Mol Neurobiol 2005;32:89-103
   PubMed Web of Science ®Google Scholar
• de la Cruz JP, Moreno A, Ruiz-Ruiz MI, et al. Effect of WEB 2086-BS, an antagonist of platelet-activating factor receptors, on retinal vascularity in diabetic rats. Eur J Pharmacol 1998;360:37-42
   Google Scholar
• Smith D, Lee EK, Saloupis P, et al. Role of neutrophils in breakdown of the blood-retinal barrier following intravitreal injection of platelet-activating factor. Exp Eye Res 1994;59:425-32
   PubMed Web of Science ®Google Scholar
• Dharma S, Bazan HE, Peyman GA, et al. Production of platelet-activating factor in photocoagulated retinas. Curr Eye Res 1991;10:1031-5
   PubMed Web of Science ®Google Scholar
• Menerath JM, Cluzel J, Droy-Lefaix MT, et al. Experimental electroretinographic exploration of retinal ischemia: preventive use of free radical scavengers and anti-PAF agents. J Ocul Pharmacol Ther 1997;13:81-8
   Google Scholar
• He YG, Wang H, Zhao B, et al. Functional analysis of platelet-activating factor in the retinal pigment epithelial cells and choroidal endothelial cells. Curr Eye Res 2009;34:957-65
   PubMed Web of Science ®Google Scholar
• Vinores SA, Xiao WH, Shen J, et al. TNF-alpha is critical for ischemia induced leukostasis, but not retinal neovascularization nor VEGF-induced leakage. J Neuroimmunol 2007;182:73-9
   PubMed Web of Science ®Google Scholar
• Doly M, Braquet P, Bonhomme B, et al. Effects of PAF-acether on electrophysiological response of isolated retina. Int J Tissue React 1987;9:33-7
   Google Scholar
• Thierry A, Doly M, Braquet P, et al. Presence of specific platelet-activating factor binding sites in the rat retina. Eur J Pharmacol 1989;163:97-101
   PubMed Web of Science ®Google Scholar
• Meyniel G, Doly M, Millerin M, et al. Involvement of PAF. Platelet-Activating Factor) in chloroquine-induced retinopathy. C R Acad Sci III 1992;314:61-5
   Google Scholar
• Doly M, Cluzel J, Millerin M, et al. Prevention of chloroquine-induced electroretinographic damage by a new platelet-activating factor antagonist, BN 50730. Ophthalmic Res 1993;25:314-18
   PubMedGoogle Scholar
• Droy-Lefaix MT, Vennat JC, Besse G, et al. Effect of Gingko biloba extract (EGb 761) on chloroquine induced retinal alterations. Lens Eye Toxic Res 1992;9:521-8
   Google Scholar
• Doly M, Millerin M, Bonhomme B, et al. Inhibition of vincristine-induced retinal impairments by a specific PAF antagonist. Lens Eye Toxic Res 1992;9:529-35
   PubMedGoogle Scholar
• Remé C, Wei Q, Munz K, et al. Light and lithium effects in the rat retina: modification by the PAF antagonist BN 52021. Graefes Arch Clin Exp Ophthalmol 1992;230:580-8
   PubMed Web of Science ®Google Scholar
• Bussolino F, Torelli S, Stefanini E, et al. Platelet-activating factor production occurs through stimulation of cholinergic and dopaminergic receptors in the chick retina. J Lipid Mediat 1989;1:283-8
   PubMedGoogle Scholar
• Beauchamp MH, Marrache AM, Hou X, et al. Platelet-activating factor in vasoobliteration of oxygen-induce retinopathy. Invest Ophthalmol Vis Sci 2002;43:3327-37
   PubMed Web of Science ®Google Scholar
• Hardy P, Beauchamp M, Sennlaub F, et al. New insights into the retinal circulation: inflammatory lipid mediators in ischemic retinopathy. Prostaglandins Leukot Essent Fatty Acids 2005;72:301-25
   PubMedGoogle Scholar
• Zhang H, Yang Y, Takeda A, et al. A Novel Platelet-Activating Factor Receptor Antagonist Inhibits Choroidal Neovascularization and Subretinal Fibrosis. PLoS One 2013;8(6):e68173
   PubMed Web of Science ®Google Scholar
• Ferreira MA, Barcelos LS, Teixeira MM, et al. Tumor growth, angiogenesis and inflammation in mice lacking receptors for platelet activating factor (PAF). Life Sci 2007;81(3):210-17
   Google Scholar
• Cao S, Walker GB, Wang X, et al. Altered cytokine profiles of human retinal pigment epithelium: oxidant injury and replicative senescence. Mol Vis 2013;19:718-28
   PubMed Web of Science ®Google Scholar
• Sung HJ, Han JI, Lee JW, et al. TCCR/WSX-1 is a novel angiogenic factor in age-related macular degeneration. Mol Vis 2012;18:234-40
   Google Scholar
• Cao X, Shen D, Patel MM, et al. Macrophage polarization in the maculae of age-related macular degeneration: a pilot study. Pathol Int 2011;61(9):528-35
   PubMed Web of Science ®Google Scholar
• Mirshahi A, Hoehn R, Lorenz K, et al. Anti-tumor necrosis factor alpha for retinal diseases: current knowledge and future concepts. J Ophthalmic Vis Res 2012;7(1):39-44
   PubMedGoogle Scholar
• Luo W, Xie F, Zhang Z, et al. Vascular adhesion protein 1 in the eye. J Ophthalmol 2013;2013:925267
   PubMed Web of Science ®Google Scholar
• Nowak JZ. Oxidative stress, polyunsaturated fatty acids-derived oxidation products and bisretinoids as potential inducers of CNS diseases: focus on age-related macula degeneration. Pharmacol Rep 2013;65(2):288-304
   PubMed Web of Science ®Google Scholar
• Dunaief JL. Iron induced oxidative damage as a potential factor in age-related macular degeneration: the Cogan Lecture. Invest Ophthalmol Vis Sci 2006;47(11):4660-4
   Google Scholar
• Hahn P, Qian Y, Dentchev T, et al. Disruption of ceruloplasmin and hephaestin in mice causes retinal iron overload and retinal degeneration with features of age-related macular degeneration. Proc Natl Acad Sci USA 2004;101(38):13850-5
   PubMed Web of Science ®Google Scholar
• Anderson OA, Finkelstein A, Shima DT. A2E induces IL-1beta production in retinal pigment epithelial cells via the NLRP3 inflammasome. PLoS One 2013;8(6):e67263
   Google Scholar
• Feeney-Burns L, Hilderbrand ES, Eldridge S. Aging human RPE: morphometric analysis of macular, equatorial, and peripheral cells. Invest Ophthalmol Vis Sci 1984;25(2):195-200
   PubMed Web of Science ®Google Scholar
• Suter M, Remé C, Grimm C, et al. Age-related macular degeneration. The lipofusion component N-retinyl-N retinylidene ethanolamine detaches proapoptotic proteins from mitochondria and induces apoptosis in mammalian retinal pigment epithelial cells. J Biol Chem 2000;275(50):39625-30
   Google Scholar
• Glenn JV, Mahaffy H, Wu K, et al. Advanced glycation end product (AGE) accumulation on Bruch’s membrane: links to age-related RPE dysfunction. Invest Ophthalmol Vis Sci 2009;50(1):441-51
   Google Scholar
• Yildirim Z, Ucgun NI, Yildirim F. The role of oxidative stress and antioxidants in the pathogenesis of age-related macular degeneration. Clinics (Sao Paulo) 2011;66(5):743-6
   PubMed Web of Science ®Google Scholar
• Barnett BP, Handa JT. Retinal microenvironment imbalance in dry age-related macular degeneration: a mini-review. Gerontology 2013;59(4):297-306
   Google Scholar
• Du H, Sun X, Guma M, et al. JNK inhibition reduces apoptosis and neovascularization in a murine model of age-related macular degeneration. Proc Natl Acad Sci USA 2013;110(6):2377-82
   PubMed Web of Science ®Google Scholar
• Guma M, Rius J, Duong-Polk KX, et al. Genetic and pharmacological inhibition of JNK ameliorates hypoxia-induced retinopathy through interference with VEGF expression. Proc Natl Acad Sci USA 2009;106(21):8760-5
   Google Scholar
• Inoue Y, Yanagi Y, Matsuura K, et al. Expression of hypoxia-inducible factor 1alpha and 2alpha in choroidal neovascular membranes associated with age-related macular degeneration. Br J Ophthalmol 2007;91(12):1720-1
   Google Scholar
• Yoshida T, Ohno-Matsui K, Ichinose S, et al. The potential role of amyloid beta in the pathogenesis of age-related macular degeneration. J Clin Invest 2005;115(10):2793-800
   PubMed Web of Science ®Google Scholar
• Thumann G. Prospectives for gene therapy of retinal degenerations. Curr Genomics 2012;13(5):350-62
   Google Scholar
• Kume K, Shimizu T. Platelet-activating factor (PAF) induces growth stimulation, inhibition, and suppression of oncogenic transformation in NRK cells overexpressing the PAF receptor. J Biol Chem 1997;272(36):22898-904
   Google Scholar
• Rollin S, Lemieux C, Maliba R, et al. VEGF-mediated endothelial P-selectin translocation: role of VEGF receptors and endogenous PAF synthesis. Blood 2004;103(10):3789-97
   Google Scholar
• Prokofyeva E, Zrenner E. Epidemiology of major eye diseases leading to blindness in Europe: a literature review. Ophthalmic Res 2012;47(4):171-88
   PubMed Web of Science ®Google Scholar